Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GW Succeeding With Cannabinoid Drug This Time Around

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug candidates targeting the cannabinoid receptors have a spotty past, so GW's successful Phase III data in pediatric epilepsy meets with great investor enthusiasm.

You may also be interested in...



GW's Epidiolex Epilepsy Data Paves Way For Cannabinoids

Safety and efficacy in study published in New England Journal of Medicine bode well for cannabinoid therapy Epidiolex, which is headed to FDA mid-year.

Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well

Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.

Advisory Committee Unanimously Rejects Sanofi’s Zimulti

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee unanimously votes against approval of Sanofi-Aventis’ rimonabant for a weight loss indication.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel